H. Keir (Dundee (Angus), United Kingdom), N. El-Merhie (Giessen, Germany)
Experimental SARS-CoV-2 human challenge in young adults
A. Mann (London, United Kingdom), B. Killingley (London, United Kingdom), M. Kalinova (London, United Kingdom), A. Anandakumar (London, United Kingdom), A. Boyers (London, United Kingdom), B. Londt (London, United Kingdom), N. Noulin (London, United Kingdom), C. Chiu (London, United Kingdom), A. Catchpole (London, United Kingdom)
|  |
Dynamics and Heterogeneity of the Lung Immunopathology in Severe COVID-19
J. Erjefalt (Lund, Sweden), N. De Souza Xavier Costa (São Paulo, Brazil), J. Jönsson (Lund, Sweden), O. Cozzolino (Lund, Sweden), K. Dantas (São Paulo, Brazil), C. Clausson (Lund, Sweden), P. Siddhuraj (Lund, Sweden), C. Lindö (Lund, Sweden), S. Ferreira Spina Lombardi (São Paulo, Brazil), A. Mendroni Júnior (São Paulo, Brazil), L. Antonangelo (São Paulo, Brazil), C. Silvério Faria (São Paulo, Brazil), A. Nunes Duarte Neto (São Paulo, Brazil), R. De Almeida Monteiro (São Paulo, Brazil), J. Rebello Pinho (São Paulo, Brazil), M. Soares Gomes-Gouvêa (São Paulo, Brazil), R. Verciano Pereira (São Paulo, Brazil), J. Sirino Monteiro (São Paulo, Brazil), J. Setubal (São Paulo, Brazil), E. Pierre De Oliveira (São Paulo, Brazil), J. Theodoro Filho (São Paulo, Brazil), C. Sanden (Lund, Sweden), J. Orengo (Tarrytown, United States), M. Sleeman (Tarrytown, United States), L. Ferraz Da Silva (São Paulo, Brazil), P. Nascimento Saldiva (São Paulo, Brazil), M. Dolhnikoff (São Paulo, Brazil), T. Mauad (São Paulo, Brazil)
|  |
Impact of the NRF2 activator, stabilised synthetic sulforaphane, on systemic inflammation in COVID19: results from the STAR-COVID19 trial
M. Long (Dundee, United Kingdom), Y. Giam (Dundee, United Kingdom), H. Abo-Leyah (Dundee, United Kingdom), R. Hull (Sheffield, United Kingdom), H. Keir (Dundee, United Kingdom), T. Pembridge (Dundee, United Kingdom), D. Alferes De Lima (Dundee, United Kingdom), B. New (Dundee, United Kingdom), S. Inglis (Dundee, United Kingdom), T. Vadiveloo (Aberdeen, United Kingdom), G. Maclennan (Aberdeen, United Kingdom), A. Gilmour (Dundee, United Kingdom), C. Hughes (Dundee, United Kingdom), L. Delgado (Dundee, United Kingdom), A. Dinkova-Kostova (Dundee, United Kingdom), J. Chalmers (Dundee, United Kingdom)
| |
Covid-19 and Cytokine Storm
L. Lopez Vergara (Zaragoza, Spain), L. Torralba (Zaragoza, Spain), C. De Diego (Zaragoza, Spain), A. Lasierra (Huesca, Spain), R. Lahoz (Zaragoza, Spain), C. Abadía (Zaragoza, Spain), P. Ruiz De Copegui (Zaragoza, Spain), J. Godino (Zaragoza, Spain), A. Cebollada (Zaragoza, Spain), B. Jimeno (Zaragoza, Spain), S. Bello (Zaragoza, Spain)
| |
Lymphocytic exhaustion in Covid-19 patients
C. De Diego Ramos (Zaragoza, Spain), L. Torralba (Zaragoza, Spain), L. López (Zaragoza, Spain), P. Ruiz De Gopegui (Zaragoza, Spain), R. Lahoz (Zaragoza, Spain), C. Abadía (Zaragoza, Spain), A. Lasierra (Huesca, Spain), A. Cebollada (Zaragoza, Spain), J. Godino (Zaragoza, Spain), B. Jimeno (Zaragoza, Spain), S. Bello (Zaragoza, Spain)
| |
A study on the morbid histopathological changes in COVID-19 patients with or without comorbidities using minimally invasive tissue sampling
A. Ray (New Delhi, India), A. Goel (New Delhi, India), D. Jain (New Delhi, India), P. Das (New Delhi, India), S. Arava (New Delhi, India), G. Singh (New Delhi, India), S. Arulselvi (New Delhi, India), N. Wig (New Delhi, India)
| |
The features of thrombogenesis in COVID-19-associated pneumonia compared to bacterial pneumonia: the key role of fibrinolysis
K. Bielosludtseva (Dniepropetrovsk, Ukraine), M. Krykhtina (Dniepropetrovsk, Ukraine), K. Dyahovets (Dniepropetrovsk, Ukraine)
| |
Cells and cytokines analysis in bronchoalveolar lavage (BAL) fluid during or after non-severe COVID-19 pneumonia.
C. Rolland-Debord (Paris, France), L. Pieroni (Paris, France), F. Bejar (Paris, France), A. Milon (Paris, France), A. Parrot (Paris, France), A. Fajac (Paris, France), J. Cadranel (Paris, France)
| |
Histopathologic changes in lung tissue after Covid-19 pneumonia
J. Tekavec-Trkanjec (Zagreb, Croatia), A. Pacic (Zagreb, Croatia), C. Tomasovic-Loncaric (Zagreb, Croatia), D. Ranilovic (Zagreb, Croatia), D. Ljubicic (Zagreb, Croatia)
| |
Impact of COVID 19 on bacterial respiratory isolates (2018-2021) from a UK tertiary cardio-thoracic ICU
S. Kaul (London, United Kingdom), V. Krishna (Chennai, India), P. Panicker (London, United Kingdom), J. Morjaria (London, United Kingdom), A. Hall (London, United Kingdom)
| |
T-cell responses to SARS-CoV-2 in patients during acute disease, convalescence and after vaccination
G. Safont-Gonzalez (Badalona, Spain), I. Latorre (Badalona, Spain), R. Villar-Hernández (Badalona, Spain), Z. Stojanovic (Badalona, Spain), A. Marín (Badalona, Spain), C. Perez-Cano (Badalona, Spain), A. Lacoma (Badalona, Spain), B. Molina-Moya (Badalona, Spain), A. Solis (Badalona, Spain), F. Armestar (Badalona, Spain), J. Matllo (Badalona, Spain), S. Díaz-Fernández (Badalona, Spain), A. Cendón (Badalona, Spain), L. Sokalchuk (Badalona, Spain), G. Tolosa (Temuco, Chile), I. Casas (Badalona, Spain), A. Rosell (Badalona, Spain), J. Dominguez (Badalona, Spain)
| |
Cell surface GRP78 functions as an alternative virus entry receptor on monocytes during SARS-CoV-2 infection
B. Han (Munich, Germany), Y. Lü (Wuhan, China), D. Moser (Munich, Germany), T. Woehrle (Munich, Germany), X. Zhou (Wuhan, China), A. Choukér (Munich, Germany), P. Lei (Wuhan, China)
| |
Human pulmonary artery endothelial cells upregulate ACE2 expression in response to iron-regulatory elements: potential implications for SARS-CoV-2 infection
Q. Toe (London, United Kingdom), T. Issitt (York, United Kingdom), A. Mahomed (London, United Kingdom), C. Sturges (London, United Kingdom), S. Wort (London, United Kingdom), G. Quinlan (London, United Kingdom)
| |
Could biological disease modifying anti rheumatic drugs (bDMARDs) and small molecules have a key role in preventing COVID-19 infection?
F. Danzo (Milano, Italy), M. Saad (Milano, Italy), S. O'Donnell (Milano, Italy), D. Spitaleri (Milano, Italy), L. Pelosi (Milano, Italy), A. Casartelli (Milano, Italy), D. Radovanovic (Milano, Italy), P. Sarzi-Puttini (Milano, Italy), P. Santus (Milano, Italy)
| |
Circulating cfDNA is an excellent marker of severity in Covid-19
L. Lopez Vergara (Zaragoza, Spain), C. De Diego (Zaragoza, Spain), L. Torralba (Zaragoza, Spain), A. Lasierra (Huesca, Spain), C. Abadía (Zaragoza, Spain), R. Lahoz (Zaragoza, Spain), P. Ruiz De Copegui (Zaragoza, Spain), J. Godino (Zaragoza, Spain), A. Cebollada (Zaragoza, Spain), B. Jimeno (Zaragoza, Spain), S. Bello (Zaragoza, Spain)
| |
T1-inflammatory endotype in patients with severe COVID-19
T. Hasegawa (Hamburg, Germany), Y. Miyamoto (Kobe, Japan), N. Iwanaga (Kobe, Japan), M. Yoshida (Kobe, Japan), Y. Kazuto (Kobe, Japan), Y. Saya (Kobe, Japan), T. Eiya (Kobe, Japan), K. Suzuki (Kobe, Japan), K. Noda (Kobe, Japan), Y. Tabe (Tokyo, Japan)
| |
Viral kinetic modeling and simulation of the impact of non-pharmaceutical COVID-19 interventions in different countries: model-informed respiratory disease trial design
I. Faddeenkov (Lyon, France), S. Arsène (Lyon, France), C. Couty (Lyon, France), N. Go (Lyon, France), S. Granjeon-Noriot (Lyon, France), D. Šmit (Lyon, France), R. Kahoul (Lyon, France), B. Illigens (Lyon, France), J. Boissel (Lyon, France), A. Chevalier (Meyrin, Switzerland), L. Lehr (Meyrin, Switzerland), C. Pasquali (Meyrin, Switzerland), A. Kulesza (Lyon, France)
| |
Late Breaking Abstract - SARS-CoV-2 load in exhaled end-tidal breath fine aerosol condensates among acutely symptomatic COVID-19 cases
S. Moschos (Newcastle Upon Tyne, United Kingdom), E. Jajah (Athens, Greece), P. Almeida (Minas Gerais, Brazil), N. Athanasiou (Athens, Greece), T. Nikolouzakis (Herakleion, Greece), J. Henderson (Newcastle Upon Tyne, United Kingdom), S. Ali (Newcastle Upon Tyne, United Kingdom), T. Mantso (Newcastle Upon Tyne, United Kingdom), D. Kofteridis (Herakleion, Greece), A. Zafiropoulos (Herakleion, Greece), C. Rokka (Athens, Greece), D. Queiroz (Minas Gerais, Brazil), A. Tsatsakis (Herakleion, Greece), P. Katsaounou (Athens, Greece), A. Kotanidou (Athens, Greece), P. Lagiou (Boston, United States), R. Aguiar (Minas Gerais, Brazil), M. Teixeira (Athens, Greece), G. Magiorkinis (Athens, Greece), P. Katsaounou (Athens, Greece)
| |
Late Breaking Abstract - SARS-CoV-2 RNA in exhaled air of hospitalized COVID-19 patients
C. van den Kieboom (Nijmegen, Netherlands), L. Kurver (Nijmegen, Netherlands), K. Lanke (Nijmegen, Netherlands), D. Diavatopoulos (Nijmegen, Netherlands), G. Overheul (Nijmegen, Netherlands), M. Netea (Nijmegen, Netherlands), J. Ten Oever (Nijmegen, Netherlands), R. Van Crevel (Nijmegen, Netherlands), K. Mulders-Manders (Nijmegen, Netherlands), F. Van De Veerdonk (Nijmegen, Netherlands), H. Wertheim (Nijmegen, Netherlands), J. Schouten (Nijmegen, Netherlands), J. Rahamat-Langendoen (Nijmegen, Netherlands), R. Van Rij (Nijmegen, Netherlands), T. Bousema (Nijmegen, Netherlands), A. Van Laarhoven (Nijmegen, Netherlands), M. De Jonge (Nijmegen, Netherlands)
| |